ReviewFrontiers in drug safety and regulation2025
Tokenization techniques for privacy-preserving healthcare data: tokenization nuts and bolts.
Review in Frontiers in drug safety and regulation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tokenization is a crucial technology for ensuring the security and privacy of patient data in clinical research, pharmacovigilance, and drug safety monitoring. As healthcare increasingly integrates diverse data sources-ranging from clinical records to non-clinical data such as social determinants of health (SDOH)-it is essential to protect sensitive patient information while improving data quality and analysis (National Institutes of Health, 2006). This article emphasizes tokenization's critical role in safeguarding privacy, particularly in pharmacovigilance activities including safety monitoring, risk assessment, and post-market surveillance. Beyond security, tokenization enriches research datasets by enabling integration of external information, thereby enhancing the rigor and reliability of pharmacovigilance outcomes. With effective tokenization, researchers can better protect patients while gaining deeper insights into clinical and pharmacological research (Cruz et al., 2024). Recent global applications validate tokenization as a foundational privacy-preserving technology in pharmacovigilance. An applied example from a psoriasis clinical trial demonstrated referential tokenization's capacity to securely link electronic health records (EHRs) and claims data across systems with greater than 99% linkage precision while maintaining privacy standards (D'Andrea et al., 2024). These capabilities align with emerging international frameworks, including the European Health Data Space (2025), reinforcing tokenization's value in generating regulatory-grade evidence for pharmacovigilance across national and multinational research environments. In many jurisdictions, tokenization that meets de-identification or pseudonymization standards may not require individual patient consent, though this varies based on data sensitivity, jurisdictional law, and the study's intent (Office for Civil Rights, 2023; EDPB, 2021).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.